Colchicine in Cardiovascular Disease

Definition

Colchicine is an ancient anti-inflammatory alkaloid that inhibits neutrophil activation and release of inflammatory chemokines (interleukin-1, interleukin-6) via microtubule disruption. It has been evaluated as a cardiovascular secondary prevention agent based on the premise that inflammation drives both acute and chronic phases of atherosclerosis. Standard cardiovascular dose: 0.5 mg once daily.

Key Concepts

Mechanism of Action

• Inhibits neutrophil chemotaxis and activation via microtubule disruption
• Suppresses NLRP3 inflammasome → reduces IL-1β and IL-6 release
• At 0.5 mg daily reduces CRP by approximately 1.28 mg/L in acute MI patients at 3 months (sources/colchicine-ami-clear-nejm-2025, rating: very high) and by ~53% in stable ASCVD (sources/CCS-AHA-2023, rating: very high)
• Biological anti-inflammatory effect is consistently demonstrated across all trial populations — the key question is whether this translates to clinical MACE reduction

Positive Trial Evidence

COLCOT (Post-Acute MI, within 30 days)

• n=4,745; colchicine 0.5 mg daily vs placebo; initiated within 30 days post-MI; 301 primary-outcome events
• Primary composite (CV death, resuscitated cardiac arrest, recurrent MI, stroke, urgent angina revascularization): HR 0.77 (P=0.02) — 23% RRR
• Benefit driven primarily by stroke and urgent revascularization components
• Excess pneumonia in colchicine arm; noncardiovascular death signal under surveillance
• (sources/ACS-AHA-2025, rating: very high)

LoDoCo2 (Stable Chronic Coronary Disease)

• n=5,522; colchicine 0.5 mg daily vs placebo; stable CAD; 451 primary-outcome events
• Primary composite (CV death, MI, ischemic stroke, ischemia-driven revascularization): 31% RRR (P<0.001)
• Trend toward excess noncardiovascular death; no excess serious infection
• (sources/CCS-AHA-2023, rating: very high)

Negative Trial Evidence (Most Recent)

CLEAR (Post-Acute MI; NEJM 2025) — LARGEST AMI TRIAL

• n=7,062; 104 centres; 14 countries; 95.1% STEMI; median follow-up 3 years; 649 primary-outcome events
• Primary composite (CV death, recurrent MI, stroke, unplanned ischemia-driven revascularization): HR 0.99 (95% CI 0.85–1.16; P=0.93) — no benefit
• CRP confirmed reduced by 1.28 mg/L at 3 months — biological effect proven; clinical translation absent
• Diarrhea increased (10.2% vs 6.6%); no excess serious infections; noncardiovascular deaths numerically lower in colchicine group
• (sources/colchicine-ami-clear-nejm-2025, rating: very high)

CHANCE-3 (Acute Ischemic Stroke)

• n=8,345; colchicine vs placebo; 534 primary-outcome events; treatment duration only 90 days
• No effect on stroke recurrence (HR 0.98; 95% CI 0.83–1.16) — possibly too short a duration
• (sources/CCS-AHA-2023, rating: very high)

CONVINCE (Ischemic Stroke; 34 months)

• n=3,154; colchicine 0.5 mg daily vs usual care; 338 primary-outcome events; median 34 months
• Composite vascular outcome: HR 0.84 (95% CI 0.68–1.05) — no significant benefit
• (sources/CCS-AHA-2023, rating: very high)

Current Guideline Positions

• ESC 2024 Chronic Coronary Syndromes: Class IIa — upgraded from IIb; issued before CLEAR data were available
• FDA: Approved colchicine for coronary artery disease — decision made before CLEAR data were available
• AHA/ACC 2023 CCD Guideline: COR 2b/B-R — 0.5 mg daily for secondary prevention of recurrent ASCVD in highest remaining-risk patients
• AHA/ACC 2025 ACS Guideline: COR IIb/B-R — cited COLCOT; noncardiovascular death signal flagged
• Emerging guidance post-CLEAR: Both ESC IIa and FDA approvals require re-evaluation in light of CLEAR (2025), CHANCE-3 (2024), and CONVINCE (2024) — three recent neutral trials

Key Safety Signals

• Diarrhea: consistently ~3–4 percentage points higher with colchicine (confirmed across all trials)
• Noncardiovascular death: signal in COPS trial (8 vs 1 deaths); not replicated in COLCOT, CLEAR, LoDoCo2, or CONVINCE; CLEAR showed lower noncardiovascular deaths in colchicine group
• Serious infections: no consistent excess; COLCOT showed excess pneumonia; LoDoCo2 and CLEAR did not
• Drug interactions: CYP3A4 and P-glycoprotein interactions; avoid with strong inhibitors (clarithromycin, cyclosporin)
• Avoid in severe renal impairment (eGFR <30 mL/min/m²)

Contradictions / Open Questions

• COLCOT/LoDoCo2 vs CLEAR/CHANCE-3/CONVINCE divergence: The two positive trials (COLCOT, LoDoCo2) enrolled earlier and showed meaningful MACE reduction; the three most recent trials (CLEAR, CHANCE-3, CONVINCE) are all neutral. The reason for divergence is unexplained. Possible explanations include: (1) background therapy intensity — CLEAR enrolled in a contemporary era with more complete revascularization, potent antiplatelet agents, and high-intensity statins; (2) CLEAR's predominantly STEMI population (95%) may respond differently to anti-inflammatory therapy than the mixed/stable population in LoDoCo2; (3) trial-period COVID-19 pandemic effects on adherence and event adjudication; (4) chance variation. (sources/colchicine-ami-clear-nejm-2025, rating: very high; sources/CCS-AHA-2023, rating: very high)
• Biological-clinical dissociation in CLEAR: Colchicine reduced CRP by 1.28 mg/L yet produced HR 0.99 for MACE. This raises fundamental questions about whether CRP reduction in post-MI patients is a valid surrogate for MACE reduction, or whether colchicine's mechanism does not target the dominant inflammatory pathways in this population.
• Twice-daily dosing subgroup in CLEAR: Patients ≥70 kg who received twice-daily colchicine in the first 90 days had HR 0.68 (95% CI 0.46–0.99) — a significant signal. Whether higher-intensity early dosing produces benefit requires a dedicated trial; not conclusive from this post-hoc subgroup.
• Guideline recalibration needed: ESC Class IIa and FDA approval both issued before CLEAR/CHANCE-3/CONVINCE. Future guideline updates will need to weigh all five large trials together; net benefit of colchicine in acute or stable coronary disease is now uncertain.
• Canakinumab vs colchicine: CANTOS (canakinumab IL-1β inhibitor) showed 15% RRR in ischemic events post-MI but excess fatal infections. Methotrexate showed no MACE benefit. ARTEMIS (ziltivekimab, 10,000 patients) is ongoing and targets a different inflammatory pathway. Divergent results across anti-inflammatory strategies highlight that the inflammatory hypothesis for MACE reduction has not been uniformly validated.

Connections

• Related to concepts/Inflammation-in-Atherosclerosis — biological rationale for anti-inflammatory therapy
• Related to concepts/Clonal-Hematopoiesis — colchicine explored as TET2-CH targeted therapy
• Related to entities/Acute-Coronary-Syndrome — post-MI colchicine use; CLEAR, COLCOT
• Related to entities/Chronic-Coronary-Disease — stable ASCVD colchicine use; LoDoCo2
• Related to concepts/ASCVD-Risk-Assessment — residual inflammatory risk concept
• Related to entities/Atrial-Cardiomyopathy — colchicine used for pericarditis management post-MI

Sources

• sources/colchicine-ami-clear-nejm-2025 — CLEAR trial (NEJM 2025): largest AMI colchicine RCT; null result
• sources/ACS-AHA-2025 — ACS 2025 guideline: COR IIb for colchicine post-ACS (COLCOT evidence)
• sources/CCS-AHA-2023 — CCD 2023 guideline: COR 2b for colchicine in stable ASCVD; LoDoCo2, CONVINCE data